Abstract Library

#4119 Interim analysis of LANTana: Phase Ib study investigating up-regulation of somatostatin receptor-2 (SSTR2) with the de-methylating agent ASTX727 to allow [177Lu]Lu-DOTA-TATE in metastatic neuroendocrine tumors (NETs)

Introduction: To be suitable for [177Lu]Lu-DOTA-TATE, SSTR2 must be present on tumor surface as per positive uptake on [68Ga]Ga-DOTA-TATE-PET/CT. SSTR2 promoter methylation reduces SSTR2 expression; this can be reversed using a demethylating agent.

Conference:

Presenting Author:

Authors: Rzeniewicz K, Ward C, Khan S, Naik M, Qurashi M,

Keywords: neuroendocrine tumor, peptide receptor radionucleotide therapy, methylation, [68Ga]Ga-DOTA-peptide-PET, [177Lu]Lu-DOTA-TATE,

#2988 Epigenetic Treatment with Histone Deacetylase Inhibitor Enhances Uptake of [111In]In-DOTA-TATE by Increased SST2 Expression on Neuroendocrine Tumor Cells

Introduction: The somatostatin-2 receptor (SST2) is a target for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NETs). By using epigenetic drugs, which can regulate gene transcription, PRRT efficacy may be further improved due to enhanced SST2 expression.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Klomp I

Authors: Klomp I, Dalm S, van Koetsveld P, Dogan-Oruç F, de Jong M,

Keywords: neuroendocrine tumors, bon-1, epigenetic, histone, histone deacetylase inhibitor, HDACi, upregulation, reversibility, somatostatin receptor-2, somatostatin,

#613 Preclinical Evaluation of Novel Combinations of 177-Lutetium Octreotate with Molecular Targeted Agents in Neuroendocrine Tumor Models

Introduction: Peptide receptor radionuclide therapy (PRRT) has been valuable in the treatment of somatostatin receptor-2 (SSTR2) expressing neuroendocrine tumors (NET) but more effective clinical regimens are needed.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Cullinane C

Authors: Cullinane C, Waldeck K, Kirby L, Eu P, Hicks R,

Keywords: preclinical models, PRRT, radiosensitizer,